<DOC>
	<DOCNO>NCT01191372</DOCNO>
	<brief_summary>The purpose study examine safety , tolerability way body handle various single multiple dos ARC19499 patient hemophilia .</brief_summary>
	<brief_title>First-in-Human Proof-of-Mechanism Study ARC19499 Administered Hemophilia Patients</brief_title>
	<detailed_description />
	<mesh_term>Hemophilia A</mesh_term>
	<mesh_term>Lipoprotein-associated coagulation inhibitor</mesh_term>
	<criteria>Adult male patient ≥18 ≤75 year age . Hemophilia type severity . Patients negative hepatitis B surface antigen ( HBsAg ) , human immunodeficiency virus ( HIV ) I II antibody test screen . Male patient , partner , willing use 2 effective , method contraception ( i.e. , self partner ) throughout study least 3 month discontinuation study drug treatment . All patient must capable understand comply protocol must sign informed consent document . Female patient ; If prophylactic coagulation factor concentrate regimen , inability unwillingness discontinue prophylaxis participation study . Existence coexist bleed disorder ( e.g. , von Willebrand Disease ) . Medical history venous arterial thromboembolism . Scheduled elective surgical procedure conduct study . Use investigational drug within 30 day study entry . Transaminase value &gt; 3 x upper limit normal ( ULN ) time screen . Haemoglobin &lt; 12.0 g/dL . Participants , opinion Investigator , significant infection know inflammatory process screening . Participants clinically relevant history presence respiratory , gastrointestinal , renal , hepatic , lymphatic , neurological , cardiovascular , psychiatric , musculoskeletal , genitourinary , immunological , dermatological , connective tissue diseases disorder . Any medical condition investigator believe would place patient increase risk result participation study e.g . history thromboembolic disease stroke . Any medication investigator considers may increase risk adverse effect study .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Hemophilia A</keyword>
	<keyword>Hemophilia B</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>pharmacodynamics</keyword>
	<keyword>Tissue Factor Pathway Inhibitor</keyword>
</DOC>